AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24906586 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Selected Healing (SH)
Number of subjects: 247
Study 24906586 — intervention group
Group type: COMPARATOR
Intervention: Control (SC)
Number of subjects: 247
Study 22261200 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 18699
Study 22261200 — intervention group
Group type: COMPARATOR
Intervention: Non-PPI gastrointestinal drugs
Number of subjects: 18699
Study 22261200 — intervention group
Group type: COMPARATOR
Intervention: No gastric therapy
Number of subjects: 18699
Study 21061562 — intervention group
Group type: COMPARATOR
Intervention: Control (CON): Attended a single motivational lecture on weight loss.
Number of subjects: 188
Study 21061562 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak Intervention (WI): Attended the motivational lecture, provided with textbooks, notebooks, and a pedometer.
Number of subjects: 188
Study 21061562 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Intervention (SI): Attended the motivational lecture, provided with the same tools as WI, and underwent a 6-month group-based support program (8 sessions).
Number of subjects: 188
Study 17686110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray 110 microg once daily (n = 605)
Number of subjects: 806
Study 17686110 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo nasal spray (n = 201)
Number of subjects: 806
Study 15729552 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction questionnaire
Number of subjects: 2772
Study 15729552 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 quality of life assessment
Number of subjects: 2772
Study 15729552 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-provider relationship, facility setting, and information on diagnosis and treatment options
Number of subjects: 2772
Study 12196372 — intervention group
Group type: COMPARATOR
Intervention: CE (cisplatin 20 mg/m(2) and etoposide 100 mg/m(2) on days 1-3)
Number of subjects: 65
Study 12196372 — intervention group
Group type: EXPERIMENTAL
Intervention: CCE (carboplatin 200 mg/m(2) on day 1, cisplatin 30 mg/m(2) on days 2-3, etoposide 100 mg/m(2) on days 1-3)
Number of subjects: 65
Study 12196372 — intervention group
Group type: COMPARATOR
Intervention: CE
Number of subjects: 65
Study 12196372 — intervention group
Group type: EXPERIMENTAL
Intervention: CCE
Number of subjects: 65
Study 9497183 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) diet
Number of subjects: 0
Study 9497183 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fat (HF) diet
Number of subjects: 0
Study 9497183 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study 9497183 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobically trained athletes
Number of subjects: 0
Study 7615269 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 days' treatment with metronidazole and eight weeks' treatment with colloidal bismuth subcitrate (CBS) (84 patients)
Number of subjects: 239
Study 7615269 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 days' treatment with metronidazole placebo and eight weeks with CBS (73 patients)
Number of subjects: 239
Study 7615269 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine (82 patients)
Number of subjects: 239
Study 7615269 — intervention group
Group type: EXPERIMENTAL
Intervention: open triple therapy (CBS 120 mg four times daily, amoxicillin 500 mg four times daily, and metronidazole 400 mg three times daily) given to patients with ulcer relapse
Number of subjects: 239
Study 7615269 — intervention group
Group type: COMPARATOR
Intervention: H pylori positive patients
Number of subjects: 239
Study 7615269 — intervention group
Group type: COMPARATOR
Intervention: H pylori negative patients
Number of subjects: 239
Study 2621541 — intervention group
Group type: EXPERIMENTAL
Intervention: WHOA! A Great Way To Say NO program
Number of subjects: 0
Study 1153813 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 (S) 15 methyl PGE2 (free acid)
Number of subjects: 125
Study 1153813 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 (S) 15 methyl PGE2 methyl ester
Number of subjects: 125
Study 1153813 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 (S) 15 methyl PGF2alpha (free acid)
Number of subjects: 125
Study 1153813 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 (S) 15 methyl PGF2alpha methyl ester
Number of subjects: 125
Study 1153813 — intervention group
Group type: EXPERIMENTAL
Intervention: mixture of 15 (S) 15 methyl PGE2 methyl ester and 15 (S) 15 methyl PGF2alpha methyl ester
Number of subjects: 125
Study 30407030 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual walking (20 min)
Number of subjects: 59
Study 30407030 — intervention group
Group type: COMPARATOR
Intervention: Virtual wheeling (control)
Number of subjects: 59
Study 28441381 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message reminder
Number of subjects: 8269
Study 28441381 — intervention group
Group type: COMPARATOR
Intervention: No text-message reminder (Control)
Number of subjects: 8269
Study 25380152 — intervention group
Group type: EXPERIMENTAL
Intervention: 10g cocoa (0, 80, 200, 500 and 800 mg cocoa flavonoids/day)
Number of subjects: 20
Study 25380152 — intervention group
Group type: EXPERIMENTAL
Intervention: 10g cocoa (80 mg cocoa flavonoids/day)
Number of subjects: 20
Study 25380152 — intervention group
Group type: EXPERIMENTAL
Intervention: 10g cocoa
Number of subjects: 20
Study 23839178 — intervention group
Group type: EXPERIMENTAL
Intervention: 3mg Drospirenone/0.02 mg Ethinyl Estradiol
Number of subjects: 25
Study 23839178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 21075695 — intervention group
Group type: EXPERIMENTAL
Intervention: Information brochure
Number of subjects: 50
Study 21075695 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention (control group)
Number of subjects: 50
Study 19434504 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week exercise intervention
Number of subjects: 101
Study 19434504 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 101
Study 19434504 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling analyses
Number of subjects: 101
Study 18604044 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic Positive Airway Pressure (BiPAP)
Number of subjects: 30
Study 18604044 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 30
Study 18604044 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 30
Study 18604044 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted Spontaneous Breathing (ASB)
Number of subjects: 30
Study 14745876 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid complex (ABLC) 2.5 mg/kg intravenously 3 times weekly
Number of subjects: 201
Study 14745876 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B (L-AmB) 3 mg/kg 3 times weekly
Number of subjects: 201
Study 11673080 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamins C and E, plus selenium)
Number of subjects: 27
Study 11673080 — intervention group
Group type: COMPARATOR
Intervention: Placebo (beverage without selenium or antioxidants)
Number of subjects: 27
Study 11673080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin‐based combination chemotherapy
Number of subjects: 27
Study 8988721 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 500 mg/body weight/day for 7 days preoperatively
Number of subjects: 20
Study 8988721 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemotherapy or radiotherapy)
Number of subjects: 20
Study 8185365 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education programme and self management plan
Number of subjects: 91
Study 8185365 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 3284754 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase plus streptodornase in saline
Number of subjects: 31
Study 3284754 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 31
Study 29043567 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 chemotherapy
Number of subjects: 380
Study 29043567 — intervention group
Group type: COMPARATOR
Intervention: Taxane therapies
Number of subjects: 380
Study 27895474 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (1.5 g/day for 10 weeks)
Number of subjects: 50
Study 27895474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 27895474 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation
Number of subjects: 50
Study 24251442 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor IX (rFIX) prophylaxis (BAX326)
Number of subjects: 0
Study 22414841 — intervention group
Group type: EXPERIMENTAL
Intervention: Access cavity filled with core build-up composite
Number of subjects: 40
Study 22414841 — intervention group
Group type: EXPERIMENTAL
Intervention: Biproximal class III cavities filled as in group 1
Number of subjects: 40
Study 22414841 — intervention group
Group type: EXPERIMENTAL
Intervention: Specimens restored as in group 2 with QFP placed
Number of subjects: 40
Study 22414841 — intervention group
Group type: EXPERIMENTAL
Intervention: Specimens decoronated and core buildup as in group 1
Number of subjects: 40
Study 22414841 — intervention group
Group type: EXPERIMENTAL
Intervention: Specimens restored as in group 4 but with QFP as in group 3
Number of subjects: 40
Study 22414841 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 40
Study 20106684 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort (Jarsin) administered t.i.d. for 15 days
Number of subjects: 12
Study 20106684 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered t.i.d. for 15 days
Number of subjects: 12
Study 18799995 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg x kg(‐1) body mass)
Number of subjects: 21
Study 18799995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 21
Study 15692981 — intervention group
Group type: EXPERIMENTAL
Intervention: Local steroid injection
Number of subjects: 163
Study 15692981 — intervention group
Group type: COMPARATOR
Intervention: Surgical decompression
Number of subjects: 163
Study 11850269 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) at 2 mg/kg body weight
Number of subjects: 0
Study 11850269 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate at 0.6 mg/kg body weight
Number of subjects: 0
Study 11850269 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome)
Number of subjects: 0
Study 11850269 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) and Amphotericin B deoxycholate
Number of subjects: 0
Study 10516938 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic testosterone regimen
Number of subjects: 20
Study 10516938 — intervention group
Group type: EXPERIMENTAL
Intervention: Superphysiologic testosterone regimen
Number of subjects: 20
Study 10516938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7627761 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar anesthesia with adrenaline (4 ml lidocaine 2% and 250 IU hyaluronidase with adrenaline)
Number of subjects: 75
Study 7627761 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia without adrenaline (4 ml lidocaine 2% and 250 IU hyaluronidase without adrenaline)
Number of subjects: 75
Study 7627761 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar anesthesia with adrenaline
Number of subjects: 75
Study 1957103 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oral salbutamol (SRS) 8 mg b.d.
Number of subjects: 49
Study 1957103 — intervention group
Group type: COMPARATOR
Intervention: Long-acting theophylline (T)
Number of subjects: 49
Study 7138719 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural morphine 0.05 mg kg‐1
Number of subjects: 20
Study 7138719 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine 0.1 mg kg‐1
Number of subjects: 20
Study 31506097 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Triple P for Baby and Mellow Bumps
Number of subjects: 0
Study 30073390 — intervention group
Group type: EXPERIMENTAL
Intervention: hu14.18-IL2 immunocytokine (IC) at 6 mg/m2/day i.v. on days 1, 2, and 3 of each 28-day course, 3 courses total.
Number of subjects: 20
Study 30073390 — intervention group
Group type: EXPERIMENTAL
Intervention: hu14.18-IL2 immunocytokine (IC)
Number of subjects: 20
Study 26874298 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating room temperature at 23°C (73°F)
Number of subjects: 791
Study 26874298 — intervention group
Group type: COMPARATOR
Intervention: Operating room temperature at 20°C (67°F)
Number of subjects: 791
Study 24671339 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (n=10)
Number of subjects: 35
Study 24671339 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (n=10)
Number of subjects: 35
Study 24671339 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 35
Study 22364352 — intervention group
Group type: EXPERIMENTAL
Intervention: Invariant manner of motion detection in infants aged 13 to 15 months (N = 30)
Number of subjects: 49
Study 22364352 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced complexity of events (dampening the figure's path) for infants aged 10 to 12 months (N = 19)
Number of subjects: 49
Study 19769548 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (QTP) + Lithium (Li) or Divalproex (DVP)
Number of subjects: 1000
Study 17714352 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% amlexanox
Number of subjects: 96
Study 17714352 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate magistral preparation
Number of subjects: 96
Study 16516075 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg clopidogrel pre-treatment for >=15 hours
Number of subjects: 1762
Study 16516075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1762
Study 14624282 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified, low-calorie diet with fat replacer (beta-glucans) and sweeteners (sucralose and fructose)
Number of subjects: 16
Study 14624282 — intervention group
Group type: COMPARATOR
Intervention: American Diabetic Association's nutrition recommendations diet
Number of subjects: 16
Study 11004030 — intervention group
Group type: EXPERIMENTAL
Intervention: perflubron emulsion at 1.2 g PFC/kg
Number of subjects: 48
Study 11004030 — intervention group
Group type: EXPERIMENTAL
Intervention: perflubron emulsion at 1.8 g PFC/kg
Number of subjects: 48
Study 11004030 — intervention group
Group type: COMPARATOR
Intervention: saline (3 mL/kg) control
Number of subjects: 48
Study 8836591 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxy-L-tryptophan (L-5-HTP) plus carbidopa
Number of subjects: 8
Study 8836591 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carbidopa
Number of subjects: 8
Study 1535490 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 246
Study 1535490 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 25 mg
Number of subjects: 246
Study 1535490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 6337266 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 0
Study 6337266 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 0
Study 6337266 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed closure of wounds
Number of subjects: 0
Study 31634295 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity (PA)
Number of subjects: 97
Study 31634295 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity (PA)
Number of subjects: 97
Study 31634295 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 97
Study 31634295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence bands of 40 to 59 steps per day and 60 to 79 steps per day
Number of subjects: 97
Study 31634295 — intervention group
Group type: COMPARATOR
Intervention: Light PA
Number of subjects: 97
Study 30198101 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital intervention for action planning
Number of subjects: 88
Study 27549782 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (individualised exercise training at home on a treadmill, telemonitoring by a physiotherapist via videoconferencing, self-management via a customised website)
Number of subjects: 120
Study 27549782 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 120
Study 27549782 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill (unsupervised exercise training at home)
Number of subjects: 120
Study 27549782 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill
Number of subjects: 120
Study 27549782 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 120
Study 27549782 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study 24756534 — intervention group
Group type: EXPERIMENTAL
Intervention: Press-fit fixation technique
Number of subjects: 158
Study 24756534 — intervention group
Group type: COMPARATOR
Intervention: Interference screw fixation
Number of subjects: 158
Study 23057417 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment (IFN)
Number of subjects: 792
Study 23057417 — intervention group
Group type: COMPARATOR
Intervention: No Interferon treatment
Number of subjects: 792
Study 23057417 — intervention group
Group type: COMPARATOR
Intervention: General resident group
Number of subjects: 792
Study 20138562 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 396
Study 20138562 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 396
Study 17413463 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and bupivacaine
Number of subjects: 103
Study 17413463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 15580451 — intervention group
Group type: EXPERIMENTAL
Intervention: 685-nm low level laser therapy
Number of subjects: 44
Study 15580451 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser treatment
Number of subjects: 44
Study 15580451 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardized wound care only)
Number of subjects: 44
Study 12380631 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 400 mg
Number of subjects: 443
Study 12380631 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 200 mg
Number of subjects: 443
Study 12380631 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 400 mg and 200 mg
Number of subjects: 443
Study 12380631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 12380631 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 1000 mg
Number of subjects: 443
Study 12380631 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 200 mg
Number of subjects: 443
Study 10428106 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine + Zidovudine + Didanosine
Number of subjects: 544
Study 10428106 — intervention group
Group type: COMPARATOR
Intervention: Two-drug combinations of Zidovudine and Didanosine
Number of subjects: 544
Study 7484866 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 7484866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2076225 — intervention group
Group type: EXPERIMENTAL
Intervention: Copalite varnish
Number of subjects: 20
Study 2076225 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelon‐Silver base
Number of subjects: 20
Study 2076225 — intervention group
Group type: COMPARATOR
Intervention: IRM base
Number of subjects: 20
Study 2076225 — intervention group
Group type: COMPARATOR
Intervention: No liner
Number of subjects: 20
Study 6908095 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight gravity drainage
Number of subjects: 110
Study 6908095 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐day progressive catheter clamping program
Number of subjects: 110
Study 30280300 — intervention group
Group type: EXPERIMENTAL
Intervention: Single pass with a radiofrequency device (6.78 MHz)
Number of subjects: 25
Study 30280300 — intervention group
Group type: COMPARATOR
Intervention: Multiple passes with a radiofrequency device
Number of subjects: 25
Study 26775711 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of TBAs/CVs for 5 days in early feeding practices
Number of subjects: 1148
Study 26775711 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and supervision of TBAs/CVs
Number of subjects: 1148
Study 26775711 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 1148
Study 26268532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal scopolamine
Number of subjects: 0
Study 26268532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25143025 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 76
Study 25143025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 22835011 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level FK778 (H) 4 x 600 mg/day (4 days) followed by 120 mg/day
Number of subjects: 364
Study 22835011 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-level FK778 (M) 3 x 600 mg/day (3 days) followed by 110 mg/day
Number of subjects: 364
Study 22835011 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level FK778 (L) 2 x 600 mg/day (2 days) followed by 100 mg/day
Number of subjects: 364
Study 22835011 — intervention group
Group type: COMPARATOR
Intervention: MMF 1 g/day (Control)
Number of subjects: 364
Study 19238303 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/die)
Number of subjects: 138
Study 17964881 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise 3 times a week for 8 weeks
Number of subjects: 21
Study 17964881 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy without exercise (Control)
Number of subjects: 21